-
公开(公告)号：US08859584B2
公开(公告)日：2014-10-14
申请号：US13716837
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC: A61K31/44 , A61K31/35 , A61K31/47 , A61K31/17 , C07D215/46 , C07D498/02 , C07D311/68 , A61K45/06 , C07D311/96 , C07D311/04 , C07C275/30 , A61K31/192 , C07D311/70 , A61K31/353 , C07D491/052 , A61K31/436 , C07D215/42 , C07C275/32
CPC classification number: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20130150409A1
公开(公告)日：2013-06-13
申请号：US13761862
申请日：2013-02-07
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Eric A. Voight
IPC: A61K31/44 , C07D401/04 , A61K31/444
CPC classification number: C07D213/30 , C07D213/50 , C07D239/26 , C07D401/12 , C07D405/12
Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb，u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US20200299246A1
公开(公告)日：2020-09-24
申请号：US16892786
申请日：2020-06-04
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Geoff T. Halvorsen , Jennifer M. Frost , Philip R. Kym
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US20200262852A1
公开(公告)日：2020-08-20
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang
IPC: C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20190224220A1
公开(公告)日：2019-07-25
申请号：US16164073
申请日：2017-04-20
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Eric Voight
IPC: A61K31/661 , C07F9/12
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
Patent Agency Ranking
公开(公告)号：US08796328B2
公开(公告)日：2014-08-05
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US10954202B2
公开(公告)日：2021-03-23
申请号：US17025644
申请日：2020-09-18
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Zhaoming Xiong , Jennifer M. Frost , Philip R. Kym , Xueqing Wang , Shuang Chen , Dennie Welch
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US20210009542A1
公开(公告)日：2021-01-14
申请号：US17025644
申请日：2020-09-18
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Zhaoming Xiong , Jennifer M. Frost , Philip R. Kym , Xueqing Wang , Shuang Chen , Dennie Welch
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US10174061B2
公开(公告)日：2019-01-08
申请号：US15715245
申请日：2017-09-26
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Brian P. Enright , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: C07F9/09 , A61K31/661 , C07F9/06 , A61K31/6615 , C07C281/02 , C07C309/24 , C07C47/277 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20180079762A1
公开(公告)日：2018-03-22
申请号：US15715245
申请日：2017-09-26
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: C07F9/09 , A61K31/661 , C07F9/06 , A61K45/06 , C07C47/277 , C07C309/24 , C07C281/02 , A61K31/6615
CPC classification number: C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.019 seconds)
